Elagolix Racemic Mixture

Status: Under Development

It is an impurity present in Elagolix, Elagolix is a gonadotropin-releasing hormone receptor antagonist that inhibits endogenous GnRH, By administration of elagolix shows results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, which leads to decreased blood concentrations of the ovarian sex hormones, estradiol, and progesterone, which is used to treat moderate to severe pain in endometriosis.

Additional information on Elagolix Racemic Mixture

Catalogue No. VE006430
Molecular Formula C32H29F5N3NaO5
Molecular Weight 653.57
Parent drug Elagolix
IUPAC Name Sodium (R, S)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2, 6-dioxo-2, 3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)amino)butanoate
Synonyms N/A
References Archer, D. F., Soliman, A. M., Agarwal, S. K., & Taylor, H. S. (2020). Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances in Reproductive Health, 14, 263349412096451. https://doi.org/10.1177/2633494120964517 ‌Lamb, Yvette N. “Elagolix: First Global Approval.” Drugs, vol. 78, no. 14, Sept. 2018, pp. 1501–8, https://doi.org/10.1007/s40265-018-0977-4. ‌
Status Under Development

Request a quote

We Respond Within a Few Hours - Whether You're a New or Existing Client

Payment Made Simple: All major Credit/Debit cards accepted

Streamlined 3-Step Process from Quotes to Orders:

Product name:

Elagolix Racemic Mixture

"*" indicates required fields

Products quotation
This field is for validation purposes and should be left unchanged.